H. Shelton Earp, MD

The UNC Lineberger team continues its tripartite research program featuring clinical and genetic breast cancer research, and is currently focused on three projects: A New and Improved Anti-HER2 Breast Cancer Vaccine; Complex Genetic Determinants of Breast Cancer Etiology and Response to Therapy; and EGF Receptor Family in Breast Cancer: The Role of HER4. Progress has been made in all three projects this year. Phase I/II trials continue, investigating the combination of vinorelbine, trastuzumab and a multi-epitope dendritic cell vaccine in the treatment of women with HER2-expressing metastatic breast cancer. The FDA has approved an amendment to the trials design allowing a change in the way that the investigators mature the patient's immune cells prior to therapeutic cell reinfusion. In the first patient tested, this resulted in the most robust anti-HER2 immune response that the Earp team has ever observed. For next year, they will pursue this new vaccine strategy in additional patients.

The second project has entered over 1,000 women (~580 with breast cancer and 460 matched women without breast cancer), obtaining blood for germline DNA extraction, as well as epidemiologic, clinical, therapeutic, and outcome data for translational studies aimed at understanding how complex genetic inheritance influences a woman�s predisposition to breast cancer and her response to therapy.

In the third project, the researchers are studying the fourth member of the EGF receptor family, HER4. Experiments have shown that one isoform of HER4 can leave the cell's surface, localize to the cell's nucleus, and slow breast cancer cell growth. Another HER4 isoform does the opposite; it stimulates growth. The scientists are developing an assay to distinguish whether a woman's breast cancer expresses the growth inhibiting or growth promoting form of HER4. This work could help explain why HER4, unlike HER2, is a good prognostic sign in some but not all human breast cancer.

Bio:
Shelton Earp is a 1970 graduate of the University of North Carolina School of Medicine. After a medical internship at Vanderbilt and service in the army, he returned to Chapel Hill where he performed his residency and fellowship, joining the faculty in 1976. He is now the Lineberger Professor of Cancer Research and a professor in the Departments of Medicine and Pharmacology. In his role as Director at the UNC Lineberger Comprehensive Cancer Center, he coordinates cancer research and care at one of the country's premier public universities, including establishment of cancer epidemiology and prevention research programs with faculty in the School of Public Health.

His own laboratory conducts clinical and translational breast cancer research as well as basic research on the behavior of cancer cells by studying the signals that regulate cell growth, differentiation and programmed cell death. His group has identified and studied genes involved in these cellular decisions. He has authored 120 biomedical-research papers and has recently received a new R01 grant, in addition to serving as Principal Investigator of the UNC Breast Cancer SPORE and UNC Lineberger Comprehensive Cancer Center grants. The UNC Breast SPORE, one of the original four Breast Cancer SPOREs, was just renewed for five years, Years 15-19.

Dr. Earp has been the recipient of UNC School of Medicine teaching awards and has served on boards and chaired national review committees for the American Cancer Society and the National Cancer Institute. He is an elected member of the American Association of Professors, the American Society of Clinical Investigation, and was recently elected to the board and as President of the American Association of Cancer Institutes. He is a recipient of The Breast Cancer Research Foundation funding for work to develop breast cancer vaccines, to understand the genetic predisposition to breast cancer, and to investigate breast cancer tumor suppressor function.